NovoCure Limited (NVCR)
USD 31.54
(-1.73%)
USD 31.54
(-1.73%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -175.86 Million USD | -97.33% |
| 2022 | -63.1 Million USD | -101.93% |
| 2021 | -38.38 Million USD | -245.83% |
| 2020 | 45.3 Million USD | 3426.15% |
| 2019 | 14.21 Million USD | 97.29% |
| 2018 | -23.44 Million USD | 14.38% |
| 2017 | -29.12 Million USD | 65.9% |
| 2016 | -108.89 Million USD | -10.89% |
| 2015 | -101.11 Million USD | -33.0% |
| 2014 | -78.19 Million USD | -14.17% |
| 2013 | -63.13 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -38.7 Million USD | -2.41% |
| 2024 Q2 | -30.74 Million USD | 16.16% |
| 2024 Q3 | -29.63 Million USD | 3.63% |
| 2023 FY | - USD | -97.33% |
| 2023 Q2 | -59.93 Million USD | 0.51% |
| 2023 Q3 | -55.44 Million USD | 7.5% |
| 2023 Q4 | -4.54 Million USD | 91.8% |
| 2023 Q1 | -60.24 Million USD | -40.19% |
| 2022 Q1 | 1.8 Million USD | 107.71% |
| 2022 Q3 | -21.95 Million USD | -18.83% |
| 2022 Q4 | -42.97 Million USD | -95.78% |
| 2022 FY | - USD | -101.93% |
| 2022 Q2 | -18.47 Million USD | -1124.06% |
| 2021 Q4 | -23.39 Million USD | -302.17% |
| 2021 FY | - USD | -245.83% |
| 2021 Q1 | 2.28 Million USD | -81.13% |
| 2021 Q2 | -9.81 Million USD | -530.11% |
| 2021 Q3 | -5.81 Million USD | 40.72% |
| 2020 FY | - USD | 3426.15% |
| 2020 Q4 | 12.09 Million USD | -29.74% |
| 2020 Q3 | 17.21 Million USD | 85.67% |
| 2020 Q2 | 9.26 Million USD | 720.83% |
| 2020 Q1 | -1.49 Million USD | -1082.24% |
| 2019 Q4 | 152 Thousand USD | -97.37% |
| 2019 Q1 | -4.18 Million USD | 51.65% |
| 2019 Q2 | 1.19 Million USD | 128.55% |
| 2019 FY | - USD | 97.29% |
| 2019 Q3 | 5.78 Million USD | 383.86% |
| 2018 Q3 | -2.93 Million USD | 38.83% |
| 2018 Q1 | -10.47 Million USD | -132.45% |
| 2018 FY | - USD | 14.38% |
| 2018 Q4 | -8.66 Million USD | -195.2% |
| 2018 Q2 | -4.79 Million USD | 54.19% |
| 2017 Q1 | -11.71 Million USD | 34.48% |
| 2017 Q2 | -13.71 Million USD | -17.13% |
| 2017 Q4 | -4.5 Million USD | -16.55% |
| 2017 Q3 | -3.86 Million USD | 71.82% |
| 2017 FY | - USD | 65.9% |
| 2016 Q1 | -30.83 Million USD | -1.98% |
| 2016 Q3 | -26.71 Million USD | 25.45% |
| 2016 Q4 | -17.87 Million USD | 33.07% |
| 2016 Q2 | -35.83 Million USD | -16.2% |
| 2016 FY | - USD | -10.89% |
| 2015 Q1 | -21.42 Million USD | 5.27% |
| 2015 FY | - USD | -33.0% |
| 2015 Q3 | -24.23 Million USD | 8.94% |
| 2015 Q2 | -26.61 Million USD | -24.26% |
| 2015 Q4 | -30.23 Million USD | -24.75% |
| 2014 FY | - USD | -14.17% |
| 2014 Q1 | -17.52 Million USD | 0.0% |
| 2014 Q2 | -20.75 Million USD | -18.39% |
| 2014 Q3 | -17.39 Million USD | 16.17% |
| 2014 Q4 | -22.61 Million USD | -30.0% |
| 2013 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -45.63 Million USD | -285.398% |
| AngioDynamics, Inc. | -14.29 Million USD | -1130.514% |
| AtriCure, Inc. | -8.1 Million USD | -2068.763% |
| Avinger, Inc. | -16.34 Million USD | -975.89% |
| Azenta, Inc. | 55.15 Million USD | 418.879% |
| BioLife Solutions, Inc. | -45.23 Million USD | -288.755% |
| The Cooper Companies, Inc. | 882.8 Million USD | 119.921% |
| Daxor Corporation | 329.74 Thousand USD | 53434.445% |
| Ekso Bionics Holdings, Inc. | -13.19 Million USD | -1232.513% |
| Femasys Inc. | -13.16 Million USD | -1235.405% |
| GlucoTrack, Inc. | -7.09 Million USD | -2380.116% |
| Harvard Bioscience, Inc. | 9.49 Million USD | 1952.576% |
| Hologic, Inc. | 1.29 Billion USD | 113.568% |
| ICU Medical, Inc. | 307.69 Million USD | 157.156% |
| Intuitive Surgical, Inc. | 2.39 Billion USD | 107.346% |
| KORU Medical Systems, Inc. | -9.39 Million USD | -1770.986% |
| LeMaitre Vascular, Inc. | 48.99 Million USD | 458.981% |
| Innovative Eyewear, Inc. | -6.57 Million USD | -2574.698% |
| Innovative Eyewear, Inc. | -6.57 Million USD | -2574.698% |
| Masimo Corporation | 236.7 Million USD | 174.299% |
| Microbot Medical Inc. | -10.63 Million USD | -1553.799% |
| Meihua International Medical Technologies Co., Ltd. | 15.77 Million USD | 1215.148% |
| Merit Medical Systems, Inc. | 231.44 Million USD | 175.987% |
| Nephros, Inc. | -1.37 Million USD | -12653.082% |
| NEXGEL, Inc. | -2.73 Million USD | -6341.941% |
| NEXGEL, Inc. | -2.73 Million USD | -6341.941% |
| Singular Genomics Systems, Inc. | -86.49 Million USD | -103.322% |
| OraSure Technologies, Inc. | 76.15 Million USD | 330.921% |
| Pro-Dex, Inc. | 8.33 Million USD | 2210.464% |
| Pulse Biosciences, Inc. | -42.36 Million USD | -315.099% |
| Predictive Oncology Inc. | -13.18 Million USD | -1234.129% |
| Precision Optics Corporation, Inc. | -2.51 Million USD | -6901.132% |
| QuidelOrtho Corporation | 545.6 Million USD | 132.233% |
| Repligen Corporation | 124.29 Million USD | 241.493% |
| Sanara MedTech Inc. | -289.09 Thousand USD | -60732.523% |
| STAAR Surgical Company | 33.22 Million USD | 629.379% |
| Sharps Technology, Inc. | -8.98 Million USD | -1858.322% |
| Utah Medical Products, Inc. | 24.8 Million USD | 808.99% |
| DENTSPLY SIRONA Inc. | 232 Million USD | 175.804% |
| Jin Medical International Ltd. | 3.44 Million USD | 5208.071% |